FDA grants orphan-drug status to Amira's drug for lung fibrosis

04/20/2011 | Xconomy

Amira Pharmaceuticals' AM152, a drug candidate for idiopathic pulmonary fibrosis, was given orphan-drug designation by the FDA. The status provides Amira seven years of market exclusivity.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA